The research, led by Kentaro Matsui of the National Center of Neurology and Psychiatry in Tokyo and the Japan Somnology Center, together with colleagues including senior author Yuichi Inoue, took advantage of a uniquely valuable resource: the Dokenpo health insurance claims database, which covers a large, anonymous Japanese population from 2019 through 2024. The investigators identified 605 patients who had been continuously using benzodiazepines or benzodiazepine receptor agonists, which include the so-called Z-drugs such as zolpidem, for at least six months before starting either suvorexant or lemborexant, the two dual orexin receptor antagonists available in Japan. To qualify, patients had to continue the orexin antagonist for at least six months, ensuring that the analysis captured sustained treatment rather than brief trials. All bedtime sedative doses were converted into diazepam equivalents, a standard metric that allows the potency of very different hypnotics to be compared on a single scale.

The study’s design is its methodological strength. Rather than comparing one group of patients against another, the researchers used a mirror-image, self-controlled approach in which each patient served as his or her own control. Dose trajectories in the six months and more before orexin antagonist initiation were compared directly with dose trajectories afterward. This design elegantly neutralizes a major source of bias in observational drug research: the stable confounders that differ between people who switch medications and those who do not. Genetics, personality, severity of insomnia, socioeconomic circumstances, and dozens of other variables that could otherwise distort results are held perfectly constant, because every patient contributes data to both sides of the comparison. What remains vulnerable to bias is primarily time-related change, such as natural fluctuation in insomnia severity or secular trends in prescribing practice, which the authors acknowledge as a limitation of the method.

The findings are striking. Before starting the orexin antagonists, the 605 patients were taking an average of 1.9 different sedative medications simultaneously, at a mean total bedtime dose of 8.2 milligrams of diazepam equivalent. After at least six months of adjunctive treatment with suvorexant or lemborexant, 42.1 percent of patients had cut their bedtime benzodiazepine or benzodiazepine receptor agonist dose by at least half, and 21.3 percent had discontinued these drugs entirely. The mean bedtime dose fell from 7.2 to 5.2 milligrams of diazepam equivalent in the suvorexant group and from 8.3 to 5.2 milligrams in the lemborexant group. For a population in which dose reduction has historically proven so difficult that many patients remain on stable hypnotic doses for a decade or more, these numbers represent a clinically meaningful shift rather than a marginal one.

The statistical modeling behind the study adds important nuance. Using logistic regression with adjustment for potential confounders, the team identified a constellation of factors that predicted success. The most powerful was age: patients aged 65 years or older had roughly two and a half times the odds of achieving a 50 percent or greater dose reduction compared with younger patients, with an odds ratio of 2.485 and a 95 percent confidence interval of 1.190 to 5.192. The same group showed similarly elevated odds of full discontinuation, at an odds ratio of 2.636. This result carries particular public health weight, because older adults are precisely the population in which benzodiazepine-related harms, from hip fractures to accelerated cognitive decline, are most devastating. A pharmacological strategy that works best in the most vulnerable patients inverts the usual risk calculus of sedative prescribing.

Two additional predictors emerged from the adjusted analyses. Patients who began with lower total benzodiazepine doses were more likely to succeed in tapering, a pattern consistent with pharmacological intuition, since lighter users face weaker physical dependence and less severe withdrawal when doses fall. And lemborexant use was independently associated with both dose reduction and discontinuation compared with suvorexant, hinting that the choice of orexin antagonist may matter. The authors caution, however, that this observational finding cannot establish that one drug is intrinsically superior; prescribing patterns, patient characteristics, and physician preferences may all have influenced which patients received which agent. Still, the signal aligns with emerging trial data, including the SUNRISE 2 study, which demonstrated the long-term efficacy and tolerability of lemborexant, and with network meta-analyses that have compared the orexin antagonists head to head.

Understanding why the strategy works requires a brief tour of sleep neurobiology. Orexin, also called hypocretin, is a neuropeptide produced by a small population of neurons in the lateral hypothalamus that stabilizes wakefulness. The loss of orexin neurons causes narcolepsy, and conversely, blocking orexin receptors promotes sleep by damping down the brain’s arousal system rather than by globally suppressing neural activity. Benzodiazepines and Z-drugs, by contrast, work through the GABA-A receptor, the same broad braking mechanism recruited by alcohol and barbiturates, which explains their sedative potency but also their liability for tolerance, dependence, respiratory effects, and next-morning impairment. Because dual orexin receptor antagonists act on an entirely separate pathway, they can maintain sleep quality while the GABAergic sedative is tapered, theoretically smoothing the transition and preventing the rebound insomnia that so often defeats deprescribing attempts. Earlier work, including the SLIM study of lemborexant switching and clinical case reports, had suggested this feasibility in smaller and more selected samples; the new claims-based analysis extends the evidence to routine clinical practice at scale.

The broader context makes the findings urgent. Prevalence studies have documented widespread hypnotic use in Japan and globally, and cohort analyses have shown that a substantial fraction of users continue these drugs for years, often at escalating doses and in risky combinations. Deprescribing guidelines recommend gradual tapering combined with cognitive behavioral therapy for insomnia, the gold standard non-pharmacological treatment, but access to behavioral therapy remains limited in many health systems, and tapering without an adequate sleep substitute frequently fails. Previous pharmacological substitution attempts, using melatonin or trazodone, produced mixed results. What the mirror-image analysis adds is real-world evidence that a systematic switching strategy with orexin antagonists can move the needle in ordinary insurance claims data, not just in carefully curated clinical trials.

Caveats remain, and the authors are careful to enumerate them. The mirror-image design cannot fully exclude secular trends or regression to the mean; patients who initiate and sustain a new medication for six months are, by definition, a selected and possibly more motivated group; and claims data cannot capture insomnia severity, cognitive behavioral therapy receipt, or the clinical reasoning behind dose changes. The database also cannot distinguish whether dose reductions were driven primarily by physician advice or patient initiative. Randomized controlled trials of DORA-assisted tapering remain the logical next step, and the odds ratios and effect sizes reported here provide exactly the kind of signal that justifies such trials. Funding for the study came from the Japan Society for the Promotion of Science KAKENHI program, and the data provider’s restrictions mean the underlying claims cannot be shared publicly.

Even with these qualifications, the study’s practical implication is hard to overstate. For clinicians confronting the entrenched problem of long-term benzodiazepine use, particularly in older patients, the results support a concrete, testable protocol: initiate suvorexant or lemborexant, stabilize sleep for several weeks, and then begin a structured taper of the GABAergic hypnotic, monitoring for withdrawal and rebound. More than four in ten patients may halve their dose, and one in five may stop entirely. Given that the alternative is often indefinite exposure to medications associated with falls, fractures, cognitive decline, and dependence, those odds transform a discouraging clinical stalemate into a genuine treatment opportunity, and they position orexin receptor antagonism as a central tool in the global effort to make sleep medicine safer.

Subject of Research: Dual orexin receptor antagonist-assisted dose reduction of benzodiazepines and benzodiazepine receptor agonists in long-term users with chronic insomnia

Article Title: Dual orexin receptor antagonist-assisted dose reduction of benzodiazepines and benzodiazepine receptor agonists: a mirror-image analysis of insurance claims data

Article References: Matsui, K., Sugiura, K., Shimura, A., Takagi, S., Kurihara, K., Takaesu, Y., & Inoue, Y. (2026). Dual orexin receptor antagonist-assisted dose reduction of benzodiazepines and benzodiazepine receptor agonists: a mirror-image analysis of insurance claims data. Journal of Clinical Sleep Medicine, 22(1), Article 163. https://doi.org/10.1007/s44470-026-00164-x

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00164-x

Keywords: insomnia, benzodiazepines, dual orexin receptor antagonists, lemborexant, suvorexant, deprescribing, hypnotics, sleep medicine, mirror-image study, claims data, older adults, drug tapering

Insomnia remains a significant global health concern, affecting nearly a third of adults at some point in their lives, with severe cases leading to profound impairments in cognitive function, mood regulation, and overall quality of life. Traditional hypnotics, such as benzodiazepines and non-benzodiazepine sedative-hypnotics, though effective in some contexts, carry risks like tolerance, dependence, and adverse cognitive effects. In contrast, dual orexin receptor antagonists, targeting the orexin system—a critical regulator of wakefulness—offer a mechanistically distinct and potentially safer approach.

The orexin neuropeptide system, comprising orexin-A and orexin-B, regulates arousal and vigilance via the orexin-1 (OX1R) and orexin-2 (OX2R) receptors in the hypothalamus. Dysfunctional hyperactivity in this system has been linked to insomnia pathophysiology, manifesting as failure to inhibit wake-promoting neurons during night time. DORAs, by antagonizing both OX1R and OX2R, promote sleep by suppressing wakefulness drive, thereby facilitating sleep initiation and maintenance without the typical sedative side-effects associated with conventional sleep aids.

This extensive meta-analysis integrates results from multiple randomized controlled trials to evaluate the efficacy and safety profiles of different DORA formulations. By leveraging network meta-analytic methods, the authors compare the relative performance of a variety of dual orexin receptor antagonists against placebo and standard treatments, enabling a hierarchical ranking based on therapeutic benefit and adverse events. Such a robust analytical approach allows for nuanced clinical recommendations tailored to patient-specific needs.

One key finding underscores that DORAs significantly enhance sleep onset latency and total sleep time compared to placebo, with consistent improvements observed across objective polysomnographic measures. Moreover, these agents demonstrate a favorable side effect profile, showing lower incidences of next-day residual sedation and cognitive impairment relative to benzodiazepine receptor agonists. This safety advantage speaks volumes about the suitability of DORAs for long-term therapy in chronic insomnia patients.

Importantly, the research identifies optimal dosing strategies that maximize benefits while minimizing adverse symptoms such as somnolence and headache. The study’s insights into dose-response relationships pave the way for personalized prescribing guidelines, ensuring that clinicians can fine-tune treatment regimens according to individual tolerance and therapeutic response. This personalized approach could mitigate the risk of overdose or under-treatment seen in broader clinical practice.

The meta-analysis also addresses the pharmacokinetic and pharmacodynamic properties of the leading dual orexin receptor antagonists, exploring their absorption, metabolism, half-life, and receptor-binding affinities. These properties bear heavily on clinical decisions, as differing half-lives influence sleep architecture and the risk of next-day sleepiness, a common concern among insomnia drug users. The data indicate that certain DORAs with intermediate half-lives strike an ideal balance for both sleep maintenance and daytime alertness.

Another facet explored is the comparative effectiveness of DORAs in diverse patient populations, including elderly individuals, who are particularly vulnerable to falls and cognitive decline when exposed to sedative medications. The analysis shows that DORAs retain their hypnotic efficacy without exacerbating fall risk or cognitive dysfunction in these groups, suggesting a critical advantage over traditional benzodiazepine-based regimens.

In addition to clinical efficacy, the study delves into mechanistic insights from neuroimaging and neurophysiological studies, illustrating how DORAs modulate sleep-wake circuitry at the cellular level. Functional MRI and EEG studies reveal decreased activation in arousal centers during sleep following administration, correlating with improved sleep quality and reduced nighttime awakenings. These mechanistic underpinnings provide compelling biological validation for the clinical findings.

Moreover, the authors emphasize the emerging role of DORAs in addressing comorbid insomnia associated with psychiatric disorders such as anxiety and depression. Given the strong bidirectional link between sleep disturbances and mental health, the ability of DORAs to improve sleep without exacerbating mood symptoms is a critical therapeutic advantage. Ongoing trials are investigating these applications, poised to expand the clinical utility of DORAs beyond primary insomnia.

The analysis also forecasts potential future developments in the pharmacotherapy of insomnia, including next-generation agents with enhanced receptor specificity or modified release profiles to further optimize efficacy and tolerability. The network meta-analysis sets a benchmark for future drug comparison studies, underlining the importance of integrating pharmacological data with real-world outcomes to shape treatment paradigms.

Overall, this seminal report from Kishi and colleagues provides a comprehensive, evidence-based framework for harnessing the full therapeutic potential of dual orexin receptor antagonists. By rigorously synthesizing data from disparate studies, the meta-analysis equips clinicians, researchers, and policymakers with critical information needed to refine insomnia treatment strategies, potentially transforming standard care and improving millions of lives globally.

With sleep disorders increasingly recognized as major public health challenges interwoven with chronic disease and mental health epidemics, this research highlights a promising frontier in sleep medicine. The dual orexin receptor antagonist class exemplifies precision pharmacology, targeting specific neurobiological pathways to restore natural sleep rhythms with minimal side effects, embodying the future of personalized brain health interventions.

The study’s publication in a leading journal underscores the rapid progress in understanding and pharmacologically modulating the orexin system. It heralds a new era where insomnia, long plagued by insufficient and problematic treatments, may soon become a manageable condition through sophisticated therapeutic targeting and patient-centric care models.

As clinical experience with DORAs expands, real-world evidence will further elucidate their long-term safety and utility, solidifying the foundation laid by this meta-analytic assessment. Integrating biochemical insights, clinical efficacy, and mechanistic neuroscience, this landmark paper signals a profound shift toward evidence-driven, biologically rational insomnia therapies.

This synthesis not only informs current clinical practice but also stimulates future research directions in neuropharmacology and sleep science. The insights gained extend beyond insomnia, potentially influencing therapeutic approaches in related neurological and psychiatric conditions where dysregulated arousal pathways are implicated.

In conclusion, the network meta-analysis led by Kishi, Ikuta, Hatano, and their team represents a pivotal milestone in sleep medicine, validating the promise of dual orexin receptor antagonists as optimal agents for insomnia treatment. Their work articulates a clear roadmap for clinical application, scientific inquiry, and drug development, catalyzing a paradigm shift in how insomnia is understood and managed worldwide.

Subject of Research: Dual orexin receptor antagonists (DORAs) for insomnia treatment and their optimal clinical use.

Article Title: Optimal use of dual orexin receptor antagonists for insomnia: a network meta-analysis perspective.

Article References:
Kishi, T., Ikuta, T., Hatano, M. et al. Optimal use of dual orexin receptor antagonists for insomnia: a network meta-analysis perspective. Transl Psychiatry 16, 149 (2026). https://doi.org/10.1038/s41398-026-03974-y

Image Credits: AI Generated

DOI: 10.1038/s41398-026-03974-y (Published 16 March 2026)